Trials / Suspended
SuspendedNCT03229876
Safety and Efficacy Evaluation of CD19-UCART
A Safety and Efficacy Study of CD19-UCART (Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor) in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
- Status
- Suspended
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Bioray Laboratories · Industry
- Sex
- All
- Age
- 1 Year – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of ascending doses of CD19-UCART in patients with relapsed or refractory B-cell hematological malignancies.
Detailed description
CD19-UCART is a kind of "off-the-shelf" product originated from health donor's PBMC.This is a open-label, dose estilation study to evaluate the safety and anti-tumor efficacy of CD19-UCART in the treatment of relapsed or refractory B-cell hematological malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CD19-UCART | A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy. |
Timeline
- Start date
- 2019-06-01
- Primary completion
- 2023-12-15
- Completion
- 2023-12-30
- First posted
- 2017-07-26
- Last updated
- 2023-07-24
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03229876. Inclusion in this directory is not an endorsement.